FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016994216> ?p ?o ?g. }

• W2016994216 endingPage "1112" @default.
• W2016994216 startingPage "1106" @default.
• W2016994216 abstract "BackgroundA diminished histamine degradation based on a reduced diaminoxidase activity is suspected as a reason for non–IgE-mediated food intolerance caused by histamine. Atopic eczema (AE) is often complicated by relapses triggered by IgE-mediated allergy to different kinds of food. However, in a subgroup of patients with AE, allergy testing proves negative, although these patients report a coherence of food intake and worsening of AE and describe symptoms that are very similar to histamine intolerance (HIT).ObjectivesIt was the aim of our study to evaluate symptoms of HIT in combination with diaminoxidase levels in a total of 360 individuals consisting of patients with AE (n = 162) in comparison with patients with HIT (n = 124) without AE and healthy control volunteers (n = 85).MethodsHistamine plasma level was determined with an ELISA and diaminoxidase serum activity with the help of radio extraction assays using [3H]-labeled putrescine-dihydrochloride as a substrate. Detailed clinical evaluations of characteristic features of AE and HIT were performed.ResultsReduced diaminoxidase serum levels leading to occurrence of HIT symptoms like chronic headache, dysmenorrhea, flushing, gastrointestinal symptoms, and intolerance of histamine-rich food and alcohol were significantly more common in patients with AE than in controls. Reduction of both symptoms of HIT and Severity Scoring of Atopic Dermatitis could be achieved by a histamine-free diet in the subgroup of patients with AE and low diaminoxidase serum levels.ConclusionHigher histamine plasma levels combined with a reduced histamine degradation capacity might influence the clinical course of a subgroup of patients with AE.Clinical implicationsAs HIT emerges in a subgroup of patients with AE, a detailed anamnestic evaluation of food intolerance and HIT symptoms complemented by an allergological screening for food allergy, a diet diary, and, in confirmed suspicion of HIT, measurement of diaminoxidase activity and a histamine-free diet should be undertaken. A diminished histamine degradation based on a reduced diaminoxidase activity is suspected as a reason for non–IgE-mediated food intolerance caused by histamine. Atopic eczema (AE) is often complicated by relapses triggered by IgE-mediated allergy to different kinds of food. However, in a subgroup of patients with AE, allergy testing proves negative, although these patients report a coherence of food intake and worsening of AE and describe symptoms that are very similar to histamine intolerance (HIT). It was the aim of our study to evaluate symptoms of HIT in combination with diaminoxidase levels in a total of 360 individuals consisting of patients with AE (n = 162) in comparison with patients with HIT (n = 124) without AE and healthy control volunteers (n = 85). Histamine plasma level was determined with an ELISA and diaminoxidase serum activity with the help of radio extraction assays using [3H]-labeled putrescine-dihydrochloride as a substrate. Detailed clinical evaluations of characteristic features of AE and HIT were performed. Reduced diaminoxidase serum levels leading to occurrence of HIT symptoms like chronic headache, dysmenorrhea, flushing, gastrointestinal symptoms, and intolerance of histamine-rich food and alcohol were significantly more common in patients with AE than in controls. Reduction of both symptoms of HIT and Severity Scoring of Atopic Dermatitis could be achieved by a histamine-free diet in the subgroup of patients with AE and low diaminoxidase serum levels. Higher histamine plasma levels combined with a reduced histamine degradation capacity might influence the clinical course of a subgroup of patients with AE." @default.
• W2016994216 created "2016-06-24" @default.
• W2016994216 creator A5031860720 @default.
• W2016994216 creator A5051230691 @default.
• W2016994216 creator A5063606457 @default.
• W2016994216 creator A5074658404 @default.
• W2016994216 creator A5089075025 @default.
• W2016994216 creator A5090246147 @default.
• W2016994216 date "2006-05-01" @default.
• W2016994216 modified "2023-10-15" @default.
• W2016994216 title "Evidence for a reduced histamine degradation capacity in a subgroup of patients with atopic eczema" @default.
• W2016994216 cites W106802015 @default.
• W2016994216 cites W1545793778 @default.
• W2016994216 cites W1550885428 @default.
• W2016994216 cites W1606564486 @default.
• W2016994216 cites W1969995914 @default.
• W2016994216 cites W1974996534 @default.
• W2016994216 cites W1976612144 @default.
• W2016994216 cites W1977360798 @default.
• W2016994216 cites W1982654107 @default.
• W2016994216 cites W1983312479 @default.
• W2016994216 cites W1985656177 @default.
• W2016994216 cites W1993116020 @default.
• W2016994216 cites W1993116859 @default.
• W2016994216 cites W1997296133 @default.
• W2016994216 cites W2003534145 @default.
• W2016994216 cites W2007484365 @default.
• W2016994216 cites W2008531458 @default.
• W2016994216 cites W2009400270 @default.
• W2016994216 cites W2016257220 @default.
• W2016994216 cites W2018842471 @default.
• W2016994216 cites W2023902247 @default.
• W2016994216 cites W2028684206 @default.
• W2016994216 cites W2031515190 @default.
• W2016994216 cites W2031752066 @default.
• W2016994216 cites W2036843343 @default.
• W2016994216 cites W2038462047 @default.
• W2016994216 cites W2041030785 @default.
• W2016994216 cites W2045561403 @default.
• W2016994216 cites W2051415381 @default.
• W2016994216 cites W2053315900 @default.
• W2016994216 cites W2058261606 @default.
• W2016994216 cites W2059105020 @default.
• W2016994216 cites W2059688604 @default.
• W2016994216 cites W2061877982 @default.
• W2016994216 cites W2070717891 @default.
• W2016994216 cites W2072379847 @default.
• W2016994216 cites W2074751207 @default.
• W2016994216 cites W2081770634 @default.
• W2016994216 cites W2086017036 @default.
• W2016994216 cites W2092906935 @default.
• W2016994216 cites W2097901958 @default.
• W2016994216 cites W2100321403 @default.
• W2016994216 cites W2100787486 @default.
• W2016994216 cites W2127353671 @default.
• W2016994216 cites W2128367977 @default.
• W2016994216 cites W2135034393 @default.
• W2016994216 cites W2141753898 @default.
• W2016994216 cites W2143138262 @default.
• W2016994216 cites W2160356240 @default.
• W2016994216 cites W2327597249 @default.
• W2016994216 cites W2341229871 @default.
• W2016994216 cites W2444379709 @default.
• W2016994216 cites W330315066 @default.
• W2016994216 cites W398195414 @default.
• W2016994216 cites W1986746889 @default.
• W2016994216 cites W2037334599 @default.
• W2016994216 doi "https://doi.org/10.1016/j.jaci.2005.11.041" @default.
• W2016994216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16675339" @default.
• W2016994216 hasPublicationYear "2006" @default.
• W2016994216 type Work @default.
• W2016994216 sameAs 2016994216 @default.
• W2016994216 citedByCount "59" @default.
• W2016994216 countsByYear W20169942162012 @default.
• W2016994216 countsByYear W20169942162013 @default.
• W2016994216 countsByYear W20169942162014 @default.
• W2016994216 countsByYear W20169942162015 @default.
• W2016994216 countsByYear W20169942162016 @default.
• W2016994216 countsByYear W20169942162017 @default.
• W2016994216 countsByYear W20169942162018 @default.
• W2016994216 countsByYear W20169942162019 @default.
• W2016994216 countsByYear W20169942162020 @default.
• W2016994216 countsByYear W20169942162021 @default.
• W2016994216 countsByYear W20169942162022 @default.
• W2016994216 countsByYear W20169942162023 @default.
• W2016994216 crossrefType "journal-article" @default.
• W2016994216 hasAuthorship W2016994216A5031860720 @default.
• W2016994216 hasAuthorship W2016994216A5051230691 @default.
• W2016994216 hasAuthorship W2016994216A5063606457 @default.
• W2016994216 hasAuthorship W2016994216A5074658404 @default.
• W2016994216 hasAuthorship W2016994216A5089075025 @default.
• W2016994216 hasAuthorship W2016994216A5090246147 @default.
• W2016994216 hasConcept C110586980 @default.
• W2016994216 hasConcept C1122143 @default.
• W2016994216 hasConcept C126322002 @default.
• W2016994216 hasConcept C141105273 @default.
• W2016994216 hasConcept C142724271 @default.
• W2016994216 hasConcept C159654299 @default.

• next